Loading clinical trials...

A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE2

A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer

A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in Patients With Advanced Hepatocellular Cancer

NCT06935175•Shanghai Zhongshan Hospital

View on ClinicalTrials.gov

Summary

The study was designed to evaluate the efficacy and safety of SHR-1826 monotherapy or in combination with immunotherapy in the treatment of advanced hepatocellular cancer patients.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1.18-75 years old, male or female.
•2.Hepatocellular carcinoma diagnosed histologically or cytologically, and not suitable for radical surgery;
•3.Failure of at least one line of standard treatment (progression or intolerance);
•4.According to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1), there is at least one measurable lesion diagnosed by imaging (a lesion that has received local treatment needs to show clear progression to be considered a measurable lesion);
•5.Expected survival time ≥ 12 weeks;
•6.Normal function of major organs;
•7.The subject voluntarily participates in this study, signs the informed consent form, has good compliance, and cooperates with the follow-up.

Exclusion Criteria

•1. Known or suspected to have a severe allergic history to the drugs related to this study (including drugs of the same type);
•2. Evidence of liver decompensation: including but not limited to symptomatic ascites, esophageal-gastric variceal bleeding, hepatic encephalopathy, hepatorenaHave central nervous system metastasis;l syndrome, sepsis, etc.;
•3. Have central nervous system metastasis;
•4. Have a history of organ transplantation or are preparing for organ transplantation (including but not limited to liver transplantation);
•5. Have a history of abdominal wall fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months before the start of treatment in the study;
•6. Other situations in which the investigator deems that the subject should not be included.

Locations (1)

Shanghai Zhongshan Hospital

Shanghai, China

Key Dates

Start Date

May 1, 2025

Primary Completion Date

May 31, 2027

Completion Date

May 31, 2028

Last Updated

April 20, 2025

Enrollment

ESTIMATED participants

Conditions

Hepatocellular Cancer

Interventions

SHR-1826

DRUG

SHR-1826 and immunotherapy combination therapy

DRUG

Contacts

Guoming Shi, M.D

CONTACT

13916969578 shi.guoming@zs-hospital.sh.cn

Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC

NCT04912765

Hepatocellular CarcinomaHepatocellular Cancer+3 more

View study

RECRUITINGPHASE2

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

NCT05451043

Pancreatic CancerHepatocellular Cancer+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 20, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer

Inclusion Criteria

Exclusion Criteria

Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers